Literature DB >> 21108571

Effects of levofloxacin, moxifloxacin and prulifloxacin on murine gut colonization by Candida albicans.

S Maraki1, S Lionakis, M Ntaoukakis, E Barbounakis, E Ntasis, D P Kofteridis, G Samonis.   

Abstract

Fluoroquinolones are broad-spectrum antibiotics increasingly utilized as empirical or prophylactic therapy in the management of cancer patients. We evaluated the effects of newer generation fluoroquinolones on the level of gastrointestinal (GI) colonization by Candida albicans in a previously established mouse model. Adult male Crl:CD1 (ICR) BR mice were fed chow containing Candida albicans or regular chow. The mice fed the Candida chow had their gut colonized by the yeast. Both groups were subsequently given levofloxacin, moxifloxacin, prulifloxacin or normal saline for 10 days. Stool cultures were performed immediately before, at the end, and one week after discontinuation of treatment to determine the level of intestinal yeast colonization. Candida-colonized mice treated with fluoroquinolones had substantially higher yeast counts in their stools than control mice fed Candida containing chow but treated with saline. Mice fed regular chow and treated with the study antibiotics or saline did not have any Candida in their stools. Dissemination of Candida to internal organs was not observed in any animal. In conclusion, we have shown that all fluoroquinolones tested induced substantial increases in the murine intestinal concentration of C. albicans.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21108571     DOI: 10.3109/13693786.2010.538443

Source DB:  PubMed          Journal:  Med Mycol        ISSN: 1369-3786            Impact factor:   4.076


  3 in total

1.  The antibacterial agent, moxifloxacin inhibits virulence factors of Candida albicans through multitargeting.

Authors:  Ashwini Jadhav; Bhagyashree Bansode; Datta Phule; Amruta Shelar; Rajendra Patil; Wasudev Gade; Kiran Kharat; Sankunny Mohan Karuppayil
Journal:  World J Microbiol Biotechnol       Date:  2017-04-13       Impact factor: 3.312

2.  Factors Influencing Non-albicans Candidemia: A Case-Case-Control Study.

Authors:  Diamantis P Kofteridis; Antonis Valachis; Dimitra Dimopoulou; Angeliki M Andrianaki; Athanasia Christidou; Sofia Maraki; Nikolaos A Spernovasilis; George Samonis
Journal:  Mycopathologia       Date:  2017-05-19       Impact factor: 2.574

Review 3.  Topoisomerase II as a target for repurposed antibiotics in Candida albicans: an in silico study.

Authors:  Ashwini Khanderao Jadhav; Sankunny Mohan Karuppayil
Journal:  In Silico Pharmacol       Date:  2021-03-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.